EGFR-mediated cell cycle regulation

Anticancer Research

Volumn 22, Issue 1 A, 2002, Pages 1-11

  Lui, Vivian Wai Yan ^a   Grandis, Jennifer Rubin ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cell cycle; EGFR combination therapies clinical trials; EGFR signaling; IMC C225

Indexed keywords

ALKALOID; ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BUSULFAN; CANCER ANTIBODY; CETUXIMAB; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; EMD 55900; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; ICR 62; IFOSFAMIDE; IMMUNOLIPOSOME; MELPHALAN; MONOCLONAL ANTIBODY 108; MONOCLONAL ANTIBODY 528; NITROSOUREA; PACLITAXEL; THIOTEPA; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER CELL; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; DNA SYNTHESIS; DOWN REGULATION; HUMAN; METASTASIS; MITOGENESIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SOMATIC CELL;

ANIMALS; CELL CYCLE; GENES, ERBB-1; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0036249493     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Growth-factor-dependent mitogenesis requires two distinct phases of signalling
2. Cell cycle checkpoints and their inactivation in human cancer
3. Cell cycle: Will the real Cdk-activating kinase please stand up
4. CDK inhibitors: Positive and negative regulators of G1-phase progression
5. Epidermal growth factor-related peptides and their receptors in human malignancies
6. Mammary gland specific hEGF receptor transgene expression induces neoplasia and inhibits differentiation
7. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma
8. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck
9. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer
10. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression
11. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: Amphiregulin and microvessel count are independent prognostic indicators of survival
12. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer
13. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
14. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas
15. Expression analyses of epidermal growth factor receptor and HER-2/neu: No advantage of prediction of recurrence or survival in breast cancer patients
16. EGF-R expression in ductal breast cancer: Proliferation and prognostic implications
17. Studies of the expression of epidermal growth factor receptor in human renal cell carcinoma: A comparison of immunohistochemical method versus ligand binding assay
18. EGFR and steroid receptors in ovarian carcinoma: Comparison with prognostic parameters and outcome of patients
19. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer
20. A comparative study of epidermal growth factor receptor (EGFR) and MDM2 gene amplification and protein immunoreactivity in human glioblastomas
21. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo
22. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer
23. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
24. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer
25. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
26. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
27. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells
28. Evidence for a role of EGF receptor in the progression of human lung carcinoma
29. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis
30. Prognostic impact of EGF-receptor in papillary thyroid carcinoma
31. Transfection of anti-sense complementary DNA of human epidermal-growth-factor receptor attenuates the proliferation of human non-small-cell-lung-cancer cells
32. Antisense epidermal growth factor receptor RNA transfection in human malignant glioma cells leads to inhibition of proliferation and induction of differentiation
33. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin
34. EGF-R dependent regulation of keratinocyte survival
35. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5
36. 1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody
37. 1 arrest in prostatic cancer cell line DU 145
38. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase
39. MDA468 growth inhibition by EGF is associated with the induction of the cyclin-dependent kinase inhibitor p21WAF1
40. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A 431 cells
41. Epidermal growth factor inhibits growth of A431 human epidermoid carcinoma in serum-free cell culture
42. Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A 431 cell growth inhibition
43. Epidermal growth factor induces cell cycle arrest and apoptosis of squamous carcinoma cells through reduction of cell adhesion
44. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma A 431 cells
45. Comparison of paclitaxel-, 5-fluoro-2′-deoxyuridine-, and epidermal growth factor (EGF)-induced apoptosis. Evidence for EGF-induced anoikis
46. Wild-type human p 53 activates the human epidermal growth factor receptor promoter
47. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity
48. 1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody
49. Cell cycle: Routine role for Ras
50. Effect of a dominant inhibitory Haras mutation on mitogenic signal transduction in NIH 3T3 cells
51. 1 phase in BALB/c 3T3 cells
52. Mitogen-activated protein kinase antisense oligonucleotide inhibits the growth of human lung cancer cells
53. Differential effects of constitutively active phosphatidylinositol 3-kinase on glucose transport, glycogen synthase activity, and DNA synthesis in 3T3-L1 adipocytes
54. Activation of phosphatidylinositol 3-kinase is sufficient for cell cycle entry and promotes cellular changes characteristic of oncogenic transformation
55. Specific activation of p85-p110 phosphatidylinositol 3′-kinase stimulates DNA synthesis by ras- and p70 S6 kinase-dependent pathways
56. Epidermal growth factor-induced phosphatidylinositol 3-kinase activation and DNA synthesis. Identification of Grb2-associated binder 2 as the major mediator in rat hepatocytes
57. Activation of STAT proteins and growth control
58. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1
59. Epidermal growth factor-induced growth inhibition requires Statl activation
60. 1 to S cell-cycle transition
61. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest
62. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro
63. Functional interaction of STAT3 transcription factor with the cell cycle inhibitor p21WAF1/CIP1/SDI1
64. Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism
65. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
66. Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity
67. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
68. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines
69. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice
70. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice
71. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma
72. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
73. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
74. Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma
75. A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas
76. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas
77. Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR62 in head and neck or lung cancer
78. Chemotherapy of neoplastic diseases
79. Principles of cancer therapy
80. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine
81. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis
82. Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor
83. Epidermal growth factor receptor family and chemosensitization
84. Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA
85. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
86. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diammine-dichloroplatinum on well established A431 cell xenografts
87. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
88. Immunogenicity and pharmacokinetic attributes of poly (ethylene glycol)-grafted immunoliposomes
89. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225
90. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
91. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radio-sensitivity in squamous cell carcinomas of the head and neck
92. Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation
93. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers
94. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor anti-body
95. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation
96. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer
97. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer